Matt Henriksen

All right.

That's good to know.

And we'll mark that on the calendar.

So next time we probably have you next year, we'll get a good update on how things are going.

Yeah.

And so, you know.

The other thing, you know, kind of longer-term project you have, and it kind of goes back to the beginning of Beta Bionics and, you know, hearing the story from Ed about, you know, his reasons for starting, you know, the company because, you know, making sure to take care of his children who were suffering from the disease.

It always started as a dual hormone company.

And so now we're kind of getting to that, you know, potentially that full circle of getting back to a dual hormone company.

For the listeners who are kind of new to that and, you know, thinking about, oh, it's just insulin delivery.

What is the second dual hormone and why is that important potentially for the patients?

Yeah, interesting.

Because then it sounds like from also from a business component, getting that insulin only pump out there allows you to now be able to generate the revenue and the potential cash flow to help finance that initial project that was going on.

Yeah.

And then, you know, just kind of closing out here, I mean, as playing your kind of CEO hat, you have a lot of different projects, you've got, you know, a lot of different, you know, and we've talked about, you know, not almost, we're almost at the state of getting to profitability for, you know, but for, you know, for a very new IPO company.

How do you make those decisions about, you know, accelerating growth or accelerating investments in one area or in one project versus, you know, being focused on that kind of, you know,

profitability trajectory and, you know, cash burn type of management.

Yeah.

Well, I look forward to following this story over the next few years.

Sean, thanks for joining us today.